Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Нимесулид: эффективность и безопасность применения
Нимесулид: эффективность и безопасность применения
Котова О.В., Акарачкова Е.С. Нимесулид: эффективность и безопасность применения. Consilium Medicum. 2016; 18 (2): 100–103. DOI: 10.26442/2075-1753_2016.2.100-103
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Нимесулид является нестероидным противовоспалительным препаратом (НПВП), эффективным в лечении целого ряда заболеваний, сопровождающихся воспалением и болью, в том числе и острой болью при первичной дисменорее. Нимесулид стал доступен на рынке с 1985 г. По степени селективности в отношении изоформ циклооксигеназы (ЦОГ) нимесулид относится к препаратам, ингибирующим преимущественно ЦОГ-2. В статье приводятся данные по эффективности и безопасности применения нимесулида.
Ключевые слова: нестероидный противовоспалительный препарат, нимесулид, эффективность, безопасность.
Key words: non-steroidal anti-inflammatory drug nimesulide, efficiency, safety.
Ключевые слова: нестероидный противовоспалительный препарат, нимесулид, эффективность, безопасность.
________________________________________________
Key words: non-steroidal anti-inflammatory drug nimesulide, efficiency, safety.
Полный текст
Список литературы
1. European Medicines Agency Summary of Product Characteristics. Annex III to the Commision Decision on Article 31 referral for nimesulide-containing medicinal products. [Accessed July 28, 2014]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Nimesulide/human_referra.... Updated January 20, 2012.
2. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
3. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–8.
4. Shah AA, Thjodleifsson B, Murray FE et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339–46.
5. Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Exp Opin Pharmacother 2001; 2: 1859–76.
6. Rainsford KD and Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161–70.
7. Bennet А, Villa G. Nimesulid: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Exp Opin Pharmacother 2000; 1: 277–6.
8. Tassorelli C, Greco R, Sandrin IG, Nappi G. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs 2003; 63 (Suppl. 1): 9–22.
9. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (PhilaPa 1976) 2000; 25 (12): 1579–85.
10. Konstantinovic L, Kahjun Z, Milovanovic A et al. Acute low back pain with radiculopathy: a double – blind, randomized, placebo-controlled study. Photomed Laser Surg 2010; 28 (4): 555–60.
11. Duffy T, Belton O, Bresnihan B et al. Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drugs 2003; 63 (Suppl. 1): 31–6.
12. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63 (Suppl. 1): 37–46.
13. Bianchi M, Ferrario P, Balzarini P et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006; 34: 348–54.
14. Чухловина М.Л. Использование препарата Найз (нимесулид) при лечении цервикогенной головной боли. Препарати та технології. 2009; 1 (57): 53–5. / Chukhlovina M.L. Ispol'zovanie preparata Naiz (nimesulid) pri lechenii tservikogennoi golovnoi boli. Preparati ta tekhnologії. 2009; 1 (57): 53–5. [in Russian]
15. Котова О.В. Назначение нестероидных противовоспалительных препаратов: соотношение эффективность/безопасность. Consilium Medicum. 2012; 14 (1): 79–82. / Kotova O.V. Naznachenie nesteroidnykh protivovospalitel'nykh preparatov: sootnoshenie effektivnost'/bezopasnost'. Consilium Medicum. 2012; 14 (1): 79–82. [in Russian]
16. Котова О.В., Акарачкова Е.С. Острые болевые синдромы в неврологической практике. Эффективная фармакотерапия. 2014; 31: 40–5. / Kotova O.V., Akarachkova E.S. Ostrye bolevye sindromy v nevrologicheskoi praktike. Effektivnaia farmakoterapiia. 2014; 31: 40–5. [in Russian]
17. Lanas A. A review of the gastrointestinal safety data gastroenterologist's perspective. Rheumatology 2010; 49 (Suppl. 2): 3–10.
18. Rostom A, Muir R, Dube C et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Patient Saf 2009; 1: 47–71.
19. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 16.
20. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
21. Traversa G, Bianchi C, DaCas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. DMJ 2003; 327: 18–22.
22. European Medicines Evalutionagency. Committee for Proprietary Medical Products. CPMP/1724/04. htpp/www.emea.eu.int.
23. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54.
24. Boelsterli U. Nimesulide and hepatic adverse еffects: roles of reactive metabolites and hostfactors. Int J Clin Pract 2002; 128: 30–6.
25. Kriegel W, Korff K, Ehrlich J et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001; 55 (8): 510–14.
26. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
27. Котова О.В.Вопросы безопасности длительной терапии нимесулидом. Фарматека. 2013; 9 (262): 54–8. / Kotova O.V.Voprosy bezopasnosti dlitel'noi terapii nimesulidom. Farmateka. 2013; 9 (262): 54–8. [in Russian]
28. Котова О.В. Остеоартроз: вопросы диагностики и лечения. Consilium Medicum. 2013; 15 (9): 45–9. / Kotova O.V. Osteoartroz: voprosy diagnostiki i lecheniia. Consilium Medicum. 2013; 15 (9): 45–9. [in Russian]
2. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
3. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–8.
4. Shah AA, Thjodleifsson B, Murray FE et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339–46.
5. Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Exp Opin Pharmacother 2001; 2: 1859–76.
6. Rainsford KD and Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161–70.
7. Bennet А, Villa G. Nimesulid: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Exp Opin Pharmacother 2000; 1: 277–6.
8. Tassorelli C, Greco R, Sandrin IG, Nappi G. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs 2003; 63 (Suppl. 1): 9–22.
9. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (PhilaPa 1976) 2000; 25 (12): 1579–85.
10. Konstantinovic L, Kahjun Z, Milovanovic A et al. Acute low back pain with radiculopathy: a double – blind, randomized, placebo-controlled study. Photomed Laser Surg 2010; 28 (4): 555–60.
11. Duffy T, Belton O, Bresnihan B et al. Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drugs 2003; 63 (Suppl. 1): 31–6.
12. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63 (Suppl. 1): 37–46.
13. Bianchi M, Ferrario P, Balzarini P et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006; 34: 348–54.
14. Chukhlovina M.L. Ispol'zovanie preparata Naiz (nimesulid) pri lechenii tservikogennoi golovnoi boli. Preparati ta tekhnologії. 2009; 1 (57): 53–5. [in Russian]
15. Kotova O.V. Naznachenie nesteroidnykh protivovospalitel'nykh preparatov: sootnoshenie effektivnost'/bezopasnost'. Consilium Medicum. 2012; 14 (1): 79–82. [in Russian]
16. Kotova O.V., Akarachkova E.S. Ostrye bolevye sindromy v nevrologicheskoi praktike. Effektivnaia farmakoterapiia. 2014; 31: 40–5. [in Russian]
17. Lanas A. A review of the gastrointestinal safety data gastroenterologist's perspective. Rheumatology 2010; 49 (Suppl. 2): 3–10.
18. Rostom A, Muir R, Dube C et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Patient Saf 2009; 1: 47–71.
19. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 16.
20. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
21. Traversa G, Bianchi C, DaCas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. DMJ 2003; 327: 18–22.
22. European Medicines Evalutionagency. Committee for Proprietary Medical Products. CPMP/1724/04. htpp/www.emea.eu.int.
23. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54.
24. Boelsterli U. Nimesulide and hepatic adverse еffects: roles of reactive metabolites and hostfactors. Int J Clin Pract 2002; 128: 30–6.
25. Kriegel W, Korff K, Ehrlich J et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001; 55 (8): 510–14.
26. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
27. Kotova O.V.Voprosy bezopasnosti dlitel'noi terapii nimesulidom. Farmateka. 2013; 9 (262): 54–8. [in Russian]
28. Kotova O.V. Osteoartroz: voprosy diagnostiki i lecheniia. Consilium Medicum. 2013; 15 (9): 45–9. [in Russian]
2. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
3. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–8.
4. Shah AA, Thjodleifsson B, Murray FE et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339–46.
5. Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Exp Opin Pharmacother 2001; 2: 1859–76.
6. Rainsford KD and Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161–70.
7. Bennet А, Villa G. Nimesulid: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Exp Opin Pharmacother 2000; 1: 277–6.
8. Tassorelli C, Greco R, Sandrin IG, Nappi G. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs 2003; 63 (Suppl. 1): 9–22.
9. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (PhilaPa 1976) 2000; 25 (12): 1579–85.
10. Konstantinovic L, Kahjun Z, Milovanovic A et al. Acute low back pain with radiculopathy: a double – blind, randomized, placebo-controlled study. Photomed Laser Surg 2010; 28 (4): 555–60.
11. Duffy T, Belton O, Bresnihan B et al. Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drugs 2003; 63 (Suppl. 1): 31–6.
12. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63 (Suppl. 1): 37–46.
13. Bianchi M, Ferrario P, Balzarini P et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006; 34: 348–54.
14. Чухловина М.Л. Использование препарата Найз (нимесулид) при лечении цервикогенной головной боли. Препарати та технології. 2009; 1 (57): 53–5. / Chukhlovina M.L. Ispol'zovanie preparata Naiz (nimesulid) pri lechenii tservikogennoi golovnoi boli. Preparati ta tekhnologії. 2009; 1 (57): 53–5. [in Russian]
15. Котова О.В. Назначение нестероидных противовоспалительных препаратов: соотношение эффективность/безопасность. Consilium Medicum. 2012; 14 (1): 79–82. / Kotova O.V. Naznachenie nesteroidnykh protivovospalitel'nykh preparatov: sootnoshenie effektivnost'/bezopasnost'. Consilium Medicum. 2012; 14 (1): 79–82. [in Russian]
16. Котова О.В., Акарачкова Е.С. Острые болевые синдромы в неврологической практике. Эффективная фармакотерапия. 2014; 31: 40–5. / Kotova O.V., Akarachkova E.S. Ostrye bolevye sindromy v nevrologicheskoi praktike. Effektivnaia farmakoterapiia. 2014; 31: 40–5. [in Russian]
17. Lanas A. A review of the gastrointestinal safety data gastroenterologist's perspective. Rheumatology 2010; 49 (Suppl. 2): 3–10.
18. Rostom A, Muir R, Dube C et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Patient Saf 2009; 1: 47–71.
19. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 16.
20. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
21. Traversa G, Bianchi C, DaCas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. DMJ 2003; 327: 18–22.
22. European Medicines Evalutionagency. Committee for Proprietary Medical Products. CPMP/1724/04. htpp/www.emea.eu.int.
23. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54.
24. Boelsterli U. Nimesulide and hepatic adverse еffects: roles of reactive metabolites and hostfactors. Int J Clin Pract 2002; 128: 30–6.
25. Kriegel W, Korff K, Ehrlich J et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001; 55 (8): 510–14.
26. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
27. Котова О.В.Вопросы безопасности длительной терапии нимесулидом. Фарматека. 2013; 9 (262): 54–8. / Kotova O.V.Voprosy bezopasnosti dlitel'noi terapii nimesulidom. Farmateka. 2013; 9 (262): 54–8. [in Russian]
28. Котова О.В. Остеоартроз: вопросы диагностики и лечения. Consilium Medicum. 2013; 15 (9): 45–9. / Kotova O.V. Osteoartroz: voprosy diagnostiki i lecheniia. Consilium Medicum. 2013; 15 (9): 45–9. [in Russian]
________________________________________________
2. Kress HG, Baltov A, Basiński A et al. Acute pain: a multifaceted challenge – the role of nimesulide. Curr Med Res Opin 2016; 32 (1): 23–36.
3. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563–8.
4. Shah AA, Thjodleifsson B, Murray FE et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339–46.
5. Bennett A, Tavares IA. COX-2 inhibitors compared and contrasted. Exp Opin Pharmacother 2001; 2: 1859–76.
6. Rainsford KD and Members of the Consensus Report Group on Nimesulide. Nimesulide – a multifactorial approach to inflammation and pain: scientific and clinical consensus. Curr Med Res Opin 2006; 22: 1161–70.
7. Bennet А, Villa G. Nimesulid: an NSAID that preferentially inhibits COX-2, and has various unique pharmacological activities. Exp Opin Pharmacother 2000; 1: 277–6.
8. Tassorelli C, Greco R, Sandrin IG, Nappi G. Central components of the analgesic/antihyperalgesic effect of nimesulide: studies in animal models of pain and hyperalgesia. Drugs 2003; 63 (Suppl. 1): 9–22.
9. Pohjolainen T, Jekunen A, Autio L, Vuorela H. Treatment of acute low back pain with the COX-2-selective anti-inflammatory drug nimesulide: results of a randomized, double-blind comparative trial versus ibuprofen. Spine (PhilaPa 1976) 2000; 25 (12): 1579–85.
10. Konstantinovic L, Kahjun Z, Milovanovic A et al. Acute low back pain with radiculopathy: a double – blind, randomized, placebo-controlled study. Photomed Laser Surg 2010; 28 (4): 555–60.
11. Duffy T, Belton O, Bresnihan B et al. Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritis. Drugs 2003; 63 (Suppl. 1): 31–6.
12. Bianchi M, Broggini M. A randomised, double-blind, clinical trial comparing the efficacy of nimesulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003; 63 (Suppl. 1): 37–46.
13. Bianchi M, Ferrario P, Balzarini P et al. Plasma and synovial fluid concentrations of nimesulide and its main metabolite after a single or repeated oral administration in patients with knee osteoarthritis. J Int Med Res 2006; 34: 348–54.
14. Chukhlovina M.L. Ispol'zovanie preparata Naiz (nimesulid) pri lechenii tservikogennoi golovnoi boli. Preparati ta tekhnologії. 2009; 1 (57): 53–5. [in Russian]
15. Kotova O.V. Naznachenie nesteroidnykh protivovospalitel'nykh preparatov: sootnoshenie effektivnost'/bezopasnost'. Consilium Medicum. 2012; 14 (1): 79–82. [in Russian]
16. Kotova O.V., Akarachkova E.S. Ostrye bolevye sindromy v nevrologicheskoi praktike. Effektivnaia farmakoterapiia. 2014; 31: 40–5. [in Russian]
17. Lanas A. A review of the gastrointestinal safety data gastroenterologist's perspective. Rheumatology 2010; 49 (Suppl. 2): 3–10.
18. Rostom A, Muir R, Dube C et al. Prevention of NSAID-related upper gastrointestinal toxicity: a meta-analysis of traditional NSAIDs with gastroprotection and COX-2 inhibitors. Drug Health Patient Saf 2009; 1: 47–71.
19. Conforti A, Leone R, Moretti U et al. Adverse drug reactions related to the use of NSAIDs with a focus on nimesulide: results of spontaneous reporting from a Northern Italian area. Drug Saf 2001; 24: 16.
20. Castellsague J, Pisa F, Rosolen V et al. Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy. Pharmacoepidemiol Drug Saf 2013; 22 (4): 365–75.
21. Traversa G, Bianchi C, DaCas R et al. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal anti-inflammatory drugs. DMJ 2003; 327: 18–22.
22. European Medicines Evalutionagency. Committee for Proprietary Medical Products. CPMP/1724/04. htpp/www.emea.eu.int.
23. Davis R, Brogden RN. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1994; 48: 431–54.
24. Boelsterli U. Nimesulide and hepatic adverse еffects: roles of reactive metabolites and hostfactors. Int J Clin Pract 2002; 128: 30–6.
25. Kriegel W, Korff K, Ehrlich J et al. Double-blind study comparing the long-term efficacy of the COX-2 inhibitor nimesulide and naproxen in patients with osteoarthritis. Int J Clin Pract 2001; 55 (8): 510–14.
26. Franchi S, Heiman F, Visentin E, Sacerdote P. Survey on appropriateness of use of nimesulide in nine European countries. Drug Healthc Patient Saf 2015; 7: 51–5.
27. Kotova O.V.Voprosy bezopasnosti dlitel'noi terapii nimesulidom. Farmateka. 2013; 9 (262): 54–8. [in Russian]
28. Kotova O.V. Osteoartroz: voprosy diagnostiki i lecheniia. Consilium Medicum. 2013; 15 (9): 45–9. [in Russian]
Авторы
О.В.Котова*, Е.С.Акарачкова
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ol_kotova@mail.ru
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*ol_kotova@mail.ru
ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава России. 119991, Россия, Москва, ул. Трубецкая, д. 8, стр. 2
*ol_kotova@mail.ru
________________________________________________
I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 2
*ol_kotova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.